Abstract: The invention relates to an process for preparing Tamsulosin hydrochloride of Formula (I) which comprises (i) reacting (R)-(?)-5-(2-amino-propyl)-2-methoxybenzenesulfonamide of Formula (II) with substituted phenoxy compound of Formula (III), wherein Z represents a removing group, such as —OSO2CH3, —OSO2C6H4CH3, —F, —Br, —Cl, or —I, in a solvent in the presence of an alkaline earth metal oxide to obtain Tamsulosin base and (ii) converting Tamsulosin base into hydrochloride salt in a solvent by addition of aqueous hydrochloric acid.

Abstract: The present invention relates to the purification of (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane (III) by making its crystalline acid addition salt, which can be used as such to produce Lopinavir/Ritonavir with high purity and yield.

Abstract: An improved process for preparing 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2?,3?-e][1,4]diazepin-6-one of Formula (I).

Abstract: The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula (I).

Abstract: The present invention relates to an improved process for preparing (2E)-3-[4-(4-fluorophenyl)-6-iso-propyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-propenal of Formula I which is an intermediate useful in the preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid]calcium salt of Formula II.

Abstract: An improved for preparing Olanzapine Form I of Formula 1 in the presence of one solvent or a mixture of solvents.

Abstract: The present invention relates to an improved process for the preparation of 2-n-butyl-3-[[2?-(1H-tetrazol-5-yl)[1,1?-biphenyl]-4-yl]-1,3-diazaspiro[4.4]non-1-en-4-one (Irbesartan).

Abstract: The present invention relates to an improved process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride of Formula I.

Abstract: The present invention relates to an improved process for the preparation of Escitalopram of the Formula (I), which comprises, isolation of Diol compound as an oxalate salt, resolution of Diol compound and cyclization of resolved compound of Formula (VII). The present invention provides a process to obtain pure Diol compound by preparing its Oxalate salt, which is useful for resolution of enantiomers.

Abstract: The present invention provides a method for the preparation of N-(1-oxopentyl)-N-[[2?-(1H-tetra-zol-5-yl)[1,1?-biphenyl]-4-yl]methyl]-L-valine (Valsartan) which comprises; treating N-[[2?-(1-triphenylmethyl-tetra-zol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester (X) with oxalic acid or its hydrates in a solvent to produce N-[[2?-(1-triph-enylmethyl-tetrazol-5-yl)biphenyl-4-yl]methy]-L-valine methyl ester oxalate (Xa) and treating the compound (Xa) with a base in a solvent followed by reacting with valeryl chloride in presence of base in a solvent to produce N-[[2?-(1-triphenylmethyl-tetra-zol-5-yl)[1,1?biphenyl]-4-yl]methyl]-N-valeryl-L-valine methyl ester (XI), de-protecting the compound (XI) using anhydrous acidic conditions to produce N-(1-oxopentyl)-N-[[2?-(1-H-tetrazol-5-yl)[1,1?biphenyl]-4-yl]methyl-L-valine methyl ester (V) followed by treating with base in a solvent to produce Valsartan.

Abstract: The present invention relates to stable aqueous oral formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral formulation of alendronate sodium. The present invention also relates to a process for the preparation of stable aqueous oral formulation of alendronate sodium.

Abstract: The invention concerns a process for producing a spinel compound of formula Li4Ti5O12, comprising a step of preparing a mixture of an organo-lithium compound selected from lithium alcoholates with an organo-titanium compound selected from titanic acid esters, in a liquid medium, and a step of hydrolyzing the mixture of said compounds. The invention also concerns a Li4Ti5O12 particulate material which may be produced according to the previous cited process and which has a BET surface area of at least 10 m2/g. The material is particularly useful in the manufacture of Lithium Ion batteries.

Abstract: An improved process for bisphosphonylation of acids, substituted acids to obtain compounds with the formula using phosphorus trihalide, phosphorus acid, in presence of phenolic compounds as diluent/solvent.

Abstract: The present invention relates to an improved process for the selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium in pure hemi-pentahydrate form of Formula (I), by first converting 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid into organic amine salt and then by replacing it with sodium salt.

Abstract: The present invention relates to an improved process for the preparation of pure Finasteride of Formula I, which comprises converting dihydrofinasteride to finasteride through novel protected dihydrofinasteride and protected finasteride intermediates.

Abstract: The present invention relates to a novel process for the preparation of a cefdinir by reacting O-acetyl thioester of Formula I with in the presence of a base in suitable solvent wherein R? represents H or any carboxyl protecting group, and then converting to the cefdinir by the removal of protecting groups. This invention also relates to making the cefdinir using a novel process to prepare the O-acetyl thioester intermediate (Formula I) by condensing (Z)-2-(2-amino-4-thiazolyl)-2-acetyloxyiminoacetic acid with bis(benzothiazol-2-yl)disulphide in the presence of triphenylphosphine and a base in a suitable solvent.

Abstract: The present invention describes an industrially advantageous process to prepare highly pure 1-Methyl-3-phenylpiperazine of Formula I that makes use of a novel piperazine derivative, 4-Benzyl-1-methyl-2-oxo-3-phenylpiperazine, represented by Formula II 1-Methyl-3-phenylpiperazine is a useful intermediate in the preparation of antidepressant Mirtazapine.

Abstract: This invention relates to a novel process to obtain highly pure 4-(cyclopropylcarbonyl)-?,?-dimethylphenylacetic acid of Formula I through crystallization from a mixture of para and meta regioisomers of Formula I and II in cyclohexane, whereby the amount of undesired meta isomer, 3-(cyclopropylcarbonyl)-?,?-dimethylphenylacetic acid of Formula II is decreased to below 0.5%. The compound of Formula I is a key intermediate for the preparation of high purity terfenadine carboxylate, which is a known antihistaminic.

Abstract: There is disclosed, a process for lactonization to produce highly pure simvastatin of Formula I which comprises lactonization of a compound of Formula II where Z is H or NH4 in a mixture of acetonitrile and glacial acetic acid under anhydrous conditions at a temperature of 65-70° C.

Abstract: There is disclosed a process for the manufacture of simvastatin of Formula I which comprises heating a compound, namely acid or ammonium salt of compound of Formula II, where Z is H or NH4 in an organic solvent at a temperature of 130-140° C.